Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: A prospective, descriptive study

Drugs and Aging

Volumn 27, Issue 1, 2010, Pages 39-50

  Tulner, Linda R ^a   Van Campen, Jos P C M ^a   Kuper, Ingeborg M J A ^a   Gijsen, George J P T ^a   Koks, Cornelis H W ^a   Mac Gillavry, Melvin R ^a   Van Tinteren, Harm ^b   Beijnen, Jos H ^a,c   Brandjes, Desiderius P M ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulants, therapeutic use; Drug utilisation; Elderly; Prescribing

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; COMORBIDITY; DRUG CONTRAINDICATION; ELECTROCARDIOGRAM; FEMALE; FRAIL ELDERLY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NETHERLANDS; PRIORITY JOURNAL; RISK FACTOR; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES;

EID: 73849098278     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11319540-000000000-00000     Document Type: Article

References (45)

1. Chatap G, Giraud K, Vincent J. Atrial fibrillation in the elderly: facts andmanagement.DrugsAging 2002; 19: 819-846
2. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-2150
3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2006; 114: 700-752
4. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579-589
5. Boode BSP, Frijling BD, Heeringa J, et al. NHG standard atrial fibrillation [in Dutch]. Huisarts Wet 2003; 46: 819-830
6. Bradley BC, Perdue KS, Tisdel KA, et al. Frequency of anticoagulation for atrial fibrillation and reasons for its nonuse at a Veterans Affairs medical center. Am J Cardiol 2000; 85: 568-572
7. Weisbord SD, Whittle J, Brooks RC. Is warfarin really underused in patients with atrial fibrillation? J Gen Intern Med 2001; 16: 743-749
8. Laguna P, Martýn A, del Arco C, et al., on behalf of the Investigators in the Spanish Atrial Fibrillation in Emergency Medicine Study Group (GEFAUR). Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study. Ann Emerg Med 2004; 44: 3-11
9. Själander A, Engström G, Berntorp E, et al. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med 2003; 254: 434-438
10. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology 1999; 53: 1319
11. Vasishta S, Toor F, Johansen A, et al. Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. Arch Gerontol Geriatr 2001; 33 (3): 219-226
12. Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians' and cardiologists' care for patients with heart failure. Am Heart J 1999; 138: 826-834
13. Villa A, Bacchetta A, Omboni E, et al. Underuse of antithrombotic therapy in stroke patients with chronic atrial fibrillation response. Stroke 2000; 21: 2266-2278
14. Ceresne L, Upshur RE. Atrial fibrillation in a primary care practice: prevalence and management. BMC Fam Prac 2002; 3: 11
15. Lipton HL, Bero LA, Bird JA, et al. Undermedication among geriatric outpatients: results of a randomized controlled trial. Ann Rev Gerontol Ger 1992; 12: 95-108
16. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-685
17. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003; 163: 1580-1586
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-383
20. Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the Medication Appropriateness Index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994; 47: 891-896
21. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-2724
22. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting strokes: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
23. Wittkowsky AK. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care 2004; 10 (10 Suppl.): S297-306
24. Heeringa J, Van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J 2006; 27: 949-953
25. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434
26. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-827
27. Pengo V, Legnani C, Noventa F, et al., on behalf of the ISCOAT study. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85: 418-422
28. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Am Heart J 2005; 149: 650-656
29. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752
30. Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin. Arch Intern Med 2006; 166: 853-859
31. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696
32. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: 167-171
33. Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc 2005; 53: 655-659
34. Brophy MT, Snyder KR, Gaehde S, et al. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004; 52: 1151-1156
35. Nair A, Hazell W, Sutton T, et al. Antithrombotic therapy in atrial fibrillation: an assessment of compliance with guidelines. N Z Med J 2005; 118 (1208): U1258
36. Hylek EM, D'Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-1080
37. Partington SL, Abid S, Teo K, et al. Pre-admission stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res 2007; 120: 663-669
38. Doucet J, Gréboval-Furstenfeld E, Tavildari A, et al. Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Fundam Clin Pharmacol 2008; 22 (5): 569-574
39. Currie CJ, Goodfellow J, McEwan P, et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with nonvalvular atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2006; 92: 196-200
40. Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503 (Pubitemid 47212371)
41. Rash A, Downes T, Portner R, et al. Thromboprophylaxis in octogenarians with atrial fibrillation: a randomised controlled trial of warfarin versus aspirin in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151-156
42. Van Deelen BAJ, van den Bemt PMLA, Egberts TCG, et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005; 22 (4): 353-360
43. Reicke B, Masuhr F, Weih M. Reasons for underuse of oral anticoagulation in atrial fibrillation-associated stroke: prospective study of German stroke patients [in German]. Fortschr Neurol Psych 2008; 76 (7): 391-395
44. Friberg L, HammarN, Ringh M, et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort Study on Atrial Fibrillation. Eur Heart J 2006; 27: 1954-1964
45. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trial translate into clinical practice? JAMA 2003; 290: 2685-2692